Presented at the 3rd Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2018; February 1–3, 2018; San Diego, California
Objectives:
Report results from SUNBEAM (NCT02294058), one of two phase 3 studies comparing once-daily ozanimod with interferon (IFN) β-1a in patients with relapsing multiple sclerosis (RMS)
Conclusions:
• Both ozanimod doses demonstrated superiority to IFN β-1a on ARR
• Adjusted mean numbers of new/enlarging T2 lesions per scan and GdE lesions at 1 year were significantly lower for both doses of ozanimod versus IFN β-1a
• Whole brain volume loss, cortical gray matter volume loss, and thalamic volume loss were reduced compared with IFN β-1a
• A dose response was consistently demonstrated across ARR and MRI efficacy endpoints
• Overall, ozanimod was well tolerated with an acceptable safety profile
• These efficacy and safety results demonstrate a favorable benefit-risk profile for ozanimod in RMS